Good Doctor Cloud Healthcare’s ailing margins belie uninspired new listing
The supplier of services for primary healthcare providers has applied for a Hong Kong IPO, reporting strong profit growth last year on non-operational factors Key Takeaways: Good Doctor Cloud Healthcare…
BRIEF: WuXi XDC profit jumps on rising revenue, improving margins
Pharmaceutical contract services provider WuXi XDC Cayman Inc. (2268.HK) said on Wednesday it expects to report its annual revenue rose 45% in 2025, as its gross profit surged over 70%…
China’s biopharma sector enters the New Year on a high
A wave of lucrative licensing deals, drug approvals and positive policy moves spurred a pharmaceutical rally in 2025, but bigger biotechs are seeing more of the benefits Key Takeaways: The…
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in…
BRIEF: Dobot partners with YSB on pharmacy-focused robots
Robot manufacturer Shenzhen Dobot Corp. Ltd. (2432.HK) on Tuesday announced a strategic collaboration with YSB Inc. (9885.HK) to jointly develop robots for pharmaceutical applications. The partnership will see Dobot spearhead…
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
Recent Articles
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
1276.HK
600276.SHG
BRIEF: Dobot partners with YSB on pharmacy-focused robots
2432.HK
9885.HK
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK
2359.HK
RELATED ARTICLES
-
Tong Ren Tang kicks off IPO leveraging time-honored medicinal brand to offer healthcare
2667.HK - Chinese medicine firm seeks elusive elixir of IPO success
- JD Health’s AI push sets up a battle of the digital doctors
- Low margins, losses dog Ringpai as it eyes Hong Kong IPO
- As messaging demand shrinks, can AI revive Xuan Wu Cloud?
